Regeneron Sees $83 Million Charge Hurting 3Q Results
By Connor Hart
Regeneron Pharmaceuticals expects to record an acquired in-process research-and-development charge of approximately $83 million in the third quarter.
The pre-tax charge stems from an $80 million up-front payment made to Hansoh Pharmaceuticals Group under the companies' previously disclosed licensing agreement, according to a Monday filing with the Securities and Exchange Commission.
Regeneron in June signed a licensing agreement with Hansoh, paying the company to develop and sell its weight loss therapy outside of China.
The pharmaceutical company said Monday the charge is expected to ding earnings and adjusted earnings each by about 68 cents a share during the third quarter. The company noted that it hasn't yet finalized its third-quarter results, which are expected to be released before the opening bell on Oct. 28.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
October 06, 2025 08:14 ET (12:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States